Biocon Raises Stake in Biocon Biologics to ~94% After Share Swap

Biocon Limited has officially ramped up its ownership in its material subsidiary, Biocon Biologics Limited (BBL), following a series of strategic share swap and cash transactions completed on 5 January 2026.

The move successfully consolidates Biocon’s control, bringing its total holding to approximately 94% of BBL’s paid-up equity share capital on a fully diluted basis.

Following approval from an extra-ordinary general meeting in late December 2025, the company has issued and allotted 17,12,79,553 equity shares on a preferential basis. These shares were issued at a price of Rs 405.78 per equity share to a group of prominent allottees, including:

• Mylan Inc.
• Serum Institute Life Sciences Private Limited (securing a 3.68% post-allotment stake in Biocon Ltd)
• Tata Capital Growth Fund II
• Activ Pine LLP

This allotment served as consideration for Biocon’s acquisition of over 261 million equity shares in Biocon Biologics.

In addition to the share swap, Biocon has moved forward with a significant cash transaction. The company completed the acquisition of 71,834,691 BBL shares from Mylan for a cash consideration of USD 200 million.

This represents the first half of a broader USD 400 million acquisition plan previously approved by the Board.

These transactions have significantly altered Biocon’s financial structure. The company’s issued, subscribed, and paid-up equity share capital has increased from approximately Rs 668.48 crore to Rs 754.12 crore.

The new equity shares will rank pari-passu with existing shares, ensuring equal standing for the new institutional holders. By centralising its ownership of the Biologics division, Biocon is positioning itself for more streamlined operations and greater strategic agility in the global biosimilars market.

Disclaimer: The information provided is for educational purposes only and does not constitute financial advice. Please conduct your own research and consult a qualified advisor before making investment decisions. Any investment decisions you make based on this information are solely at your own risk.

---